AstraZeneca Results Presentation Deck
Continuing response to COVID-19
Status on vaccine and anti-viral antibody
COVID-19 vaccine
clinical and real-world data
US Phase III met the primary
endpoint with 76% vaccine
efficacy
Real-world data from UK rollout
showing >80% protection against
hospitalisation¹
73% effective 35 days after first
dose in older adults²
Potential to play a significant
role in defeating the pandemic
1. Bernal JL et al., preprint published online, The Lancet. 2021 2. Hyams C et al.,
preprint published online, The Lancet. 2021.
27
COVID-19 vaccine
rollout
68m doses invoiced globally
COVAX initiative has reached 100
countries
Supply continuing to ramp with
production yields improving
Work on new variants begun
Granted conditional approval or
emergency use in c.80 countries
AZD7442 long-acting
antibody combo
Potential to offer immediate
protection
Late-stage trials in both
prophylaxis and treatment.
US Government agreements for
potential supply of 700,000 doses
First data
in H1 2021
3View entire presentation